Abstract 5579
Background
One of the critical ethical requirements of conducting clinical research regardless of the study setting is to obtain informed consent before enrolling subjects’ participants. It is crucial to ensure quality and validity of the informed consent of study’s participants.
Methods
We used a quantitative survey design using the Italian validated version of the Quality of Informed Consent (QuIC) questionnaire. We included 7 Italian cancer sites and 300 clinical trials patients.
Results
All the patients invited accepted to fill the questionnaire. Most of them were male (N = 130), and the mean age was 60 (sd 10). Most of them were satisfied with the information received, and they considered themselves to be well informed. The average score for objective understanding was 62.2 and for subjective understanding was 74.6 (p < 0.001). Subjects responded correctly to questions about the general understanding of participation in research. Only 33% understood which procedures were experimental, and 40% of respondents knew foreseeable risks or discomfort from the research. In ANOVA analysis, an increased understanding was associated with a higher level of education.
Conclusions
Our results suggest that investigators should invest more effort to improve clinical trials subjects reach a safer understanding of the informed consent. The clinical trials nursing role is crucial to protect the clinical trial participants rights.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gianluca Catania.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract